Te­va re­port­ed­ly con­sid­er­ing sale of API unit

Te­va is re­port­ed­ly con­sid­er­ing a sale of its ac­tive phar­ma­ceu­ti­cal in­gre­di­ents busi­ness amid a wider strate­gic shift for the com­pa­ny.

The Is­raeli drug­mak­er has hired ad­vi­sors to test out whether there is in­ter­est in buy­ing the busi­ness unit in a deal val­ued at about $2 bil­lion, peo­ple fa­mil­iar with the mat­ter told BNN Bloomberg.

Te­va’s API busi­ness cur­rent­ly em­ploys about 4,000 peo­ple at 14 pro­duc­tion sites across the globe mak­ing around 350 prod­ucts.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER